Entera and OPKO, to upgrade the PTH tablet

Introduction

One of Miami’s diamonds, OPKO Healthcare Company, is working to establish robust pharmaceutical products for extreme conditions and continues to operate under BioReference Laboratories' supervision. The company is engaged in the development of treatments such as NGENLA and Rayaldee, concentrating on multispecific antibody therapies.

Entera Bio is an Israeli biopharmaceutical company that operates confidently in the oral delivery of large-molecule peptide therapeutics with the help of its exclusive N-Tab™ technology. The company brings alternatives to the injections and introduces effective tablets to treat metabolic diseases such as hypoparathyroidism and osteoporosis.

Announcement

Enetra and OPKO came together to renew their License agreement and continue their partnership promise to upgrade the first-ever oral long-surviving PTH analog as one time tablet for the hypoparathyroidism patient group. The collaboration has stood strong with the merger of Entera’s exclusive N-Tab® technology and OPKO’s long-acting PTH variants.

Both companies equally contribute to advancing the tablet plan. The companies planned to leverage the development and submit the IND application this year itself. This decision came into the limelight after the pharmacokinetic and pharmacodynamic data.

Expanded partnerships’ revamp

Under this renewal of partnership, each of the companies will get a 50% of perk of pro-rata ownership interest in this promising LA-PTH hypoparathyroidism program. Further, both companies will be liable to contribute 50% wealth in the development of the program. Apart from this, the cost-sharing (transaction) and ownership built-up of 60% (OPKO) and 40% (Entera) is same for the OXM program based on fibrotic and metabolic disorders.

This year, there is a new member to be a part of this extended partnership legacy, the new Executive Vice President of Administration and Director at OPKO, Mr Steve Rubin. With his long years of smart oversight of drug establishment throughout its various excellence in public biotechnology companies, and additionally, his work in corporate governance is appreciated.

What leaders have to say about this extended partnership?

Chief Executive Officer of Entera, Miranda Toledano, said, “This partnership with OPKO is from 2023, and it's been very learning. The oral GLP-2 and OXM have illustrated powerful bioavailability and profiles. Moreover, the oral LA-PTH preclinical data show full potential to transition the hypoparathyroidism picture.”

Chief Executive Officer and Chairman of OPKO Health, MD, Philip Frost, said, “We are grateful to extend our partnership with Entera to upgrade this long-acting PTH program for the disturbing hypoparathyroidism condition.”